ライフサイエンスコーパス: distant metastasis

1 sectable (286 locally unresectable, 244 with distant metastasis).

2 vour the tumour microenvironment in terms of distant metastasis.

3 ntify a tight selective bottleneck preceding distant metastasis.

4 liac node metastasis, and 44 (9.9%) had more distant metastasis.

5 th no such metastasis and patients with more distant metastasis.

6 ks analysis was used to estimate the risk of distant metastasis.

7 (CTC) disseminating is an important cause of distant metastasis.

8 nt for tumour cell invasion and promotion of distant metastasis.

9 were used to estimate hazard ratios (HRs) of distant metastasis.

10 10-4) were associated with increased risk of distant metastasis.

11 e and selection operator was used to predict distant metastasis.

12 ast cancer tumor prognosticators and risk of distant metastasis.

13 The primary endpoint was the development of distant metastasis.

14 tumor extension (P=0.017) were predictive of distant metastasis.

15 read and recurrence resulting from local and distant metastasis.

16 prostate tumor formation, local invasion and distant metastasis.

17 tumors may be associated with more frequent distant metastasis.

18 early breast cancers experience relapse with distant metastasis.

19 tribute to the initiation and progression of distant metastasis.

20 ients have poor prognosis after formation of distant metastasis.

21 ion with radiation, and decrease the risk of distant metastasis.

22 higher probability of nodal involvement and distant metastasis.

23 5 are upregulated in both primary tumors and distant metastasis.

24 ant metastasis to avoid confounding by other distant metastasis.

25 (PET) scan revealed no evidence of nodal or distant metastasis.

26 ouraged for newly diagnosed patients without distant metastasis.

27 logical intervention specifically to prevent distant metastasis.

28 elate significantly with cancer survival and distant metastasis.

29 entation, (2) lymph node metastasis, and (3) distant metastasis.

30 C and EMT programs in local invasiveness and distant metastasis.

31 which also resulted in widespread local and distant metastasis.

32 rove the long-term survival of patients with distant metastasis.

33 sive due to high incidence of recurrence and distant metastasis.

34 term risk of several cancers and the risk of distant metastasis.

35 s: local disease, cervical nodal spread, and distant metastasis.

36 ssociated with tumor staging, lymph node and distant metastasis.

37 ors and associated with invasive disease and distant metastasis.

38 ciation between miRNA expression and risk of distant metastasis.

39 GLK transgenic mice displayed enhanced distant metastasis.

40 ncer cell migration and invasion, as well as distant metastasis.

41 interactions promoting the establishment of distant metastasis.

42 ifocality, lymphovascular invasion, nodal or distant metastasis.

43 moderately predictive of risk of subsequent distant metastasis.

44 e-free survival and reduction in the rate of distant metastasis.

45 help to identify those at increased risk of distant metastasis.

46 mples and was linked to an increased risk of distant metastasis.

47 re recorded, and all patients were free from distant metastasis.

48 irculating PCa cells and subsequently reduce distant metastasis.

49 tumorigenic fitness during the evolution of distant metastasis.

50 odifications during the natural evolution of distant metastasis.

51 ference standard, reviewed PET/CT images for distant metastasis.

52 subtype, CREB3L1 expression is predictive of distant metastasis.

53 ry site was associated with a lower risk for distant metastasis (0.1 [0.0-0.7]) and improved survival

54 tant disease-free survival (hazard ratio for distant metastasis, 0.62; P=0.02) and the 10-year rate o

55 the placebo group (hazard ratio for death or distant metastasis, 0.76; 95.8% CI, 0.64 to 0.92; P=0.00

56 (19.9% v. 25.9%, respectively; P = .97), or distant metastasis (13.0% v. 9.7%, respectively; P = .08

57 had locoregional recurrence and one (2%) had distant metastasis; 2-year progression-free survival was

58 HR, 0.70; 95% CI, 0.51 to 0.96), and time to distant metastasis (adjusted HR, 0.69; 95% CI, 0.59 to 0

59 ation to aspirin reduced risk of cancer with distant metastasis (all cancers, hazard ratio [HR] 0.64,

60 (ILRR) of breast cancer have a high risk of distant metastasis and death from breast cancer.

61 se was significantly associated with reduced distant metastasis and death from causes other than canc

62 ology and anaplasia grading as predictors of distant metastasis and death showed that high-risk histo

63 ith clinical stage, pathologic tumor status, distant metastasis and decreased survival of pancreatic

64 Ten-year cumulative incidence of distant metastasis and DFS were 10.5% and 89.5% for pati

65 including cancers, with higher risks of both distant metastasis and early recurrence.

66 We examined 281 lung cancer patients with distant metastasis and found that smokers exhibited a si

67 nalysis, tumor size, lymph node involvement, distant metastasis and histologic grade were correlated

68 shed a prometastatic role for cathepsin B in distant metastasis and illustrated the therapeutic benef

69 Reduction in distant metastasis and improvements in cancer outcomes a

70 s a problem-solving role in the detection of distant metastasis and in posttreatment evaluation.

71 that miR-1 expression is further reduced in distant metastasis and is a candidate predictor of disea

72 was 22% (95% CI, 12%-32%); 5-year actuarial distant metastasis and locoregional recurrence were 54%

73 hirteen patients have primary tumors without distant metastasis and matched normal tissues.

74 y, cell cycle defects, poor differentiation, distant metastasis and metaplasia.

75 ccess the systemic circulation, resulting in distant metastasis and mortality.

76 possibility of lymph-node involvement but no distant metastasis and no microscopic residual disease,

77 gative correlation with lymph node invasion, distant metastasis and patient survival in examinations

78 circulating neutrophils are associated with distant metastasis and poor outcome in a number of epith

79 st tumours are significantly associated with distant metastasis and poor outcome in breast cancer pat

80 IF-1 and HIF-2 are associated with increased distant metastasis and poor survival in a variety of tum

81 in levels shown previously to correlate with distant metastasis and poor survival.

82 nificantly correlated with increased risk of distant metastasis and reduced relapse-free and overall

83 e and is highly prognostic for occurrence of distant metastasis and survival in colon cancer patients

84 The true detection rate of distant metastasis and synchronous cancer was assessed f

85 study was to determine the detection rate of distant metastasis and synchronous cancer, comparing cli

86 dence of mediastinal lymph node involvement, distant metastasis, and 12-mo mortality.

87 65.2% had 1 site of distant metastasis, and 42.9% had bone-only metastases.

88 he cumulative incidence of local recurrence, distant metastasis, and disease-free survival (DFS).

89 positive human BC, correlates with increased distant metastasis, and is an independent predictor of p

90 , progression-free survival (PFS), actuarial distant metastasis, and locoregional recurrence.

91 my, breast cancer-specific survival, time to distant metastasis, and overall survival (OS).

92 drive primary tumor growth, regional spread, distant metastasis, and patient death.

93 ing loss of differentiation, local invasion, distant metastasis, and rapid lethality.

94 ), progression-free survival, local failure, distant metastasis, and selected Common Terminology Crit

95 egions where BC cells first establish before distant metastasis, and the presence of tumor cells in t

96 imilarly poor survival as patients with more distant metastasis, and thus may not benefit from surger

97 l differences such as lymph node metastasis, distant metastasis, and triple-negative behavior of tumo

98 risk of local recurrence, lymphatic spread, distant metastasis, and tumor-related death in patients

99 2 cm) and any N stage, or pT2N0; absence of distant metastasis; and no iodine contamination.

100 f the breast, and even more significantly in distant metastasis arising after failed chemotherapy.

101 r relapse-free survival and survival without distant metastasis as the site of the first relapse.

102 related with synchronous liver metastasis or distant metastasis-associated disease relapse.

103 diotherapy (n=78) had a greater incidence of distant metastasis at 10 years than did their untreated

104 imary end point was the rate of freedom from distant metastasis at 3 years (DMF3).

105 evealed that, in addition to the presence of distant metastasis at diagnosis (P = 0.001 and 0.001, re

106 verall survival among those who present with distant metastasis at diagnosis (stage 4).

107 ement and one-third of patients already have distant metastasis at diagnosis.

108 ubtype of lung cancer and has a high risk of distant metastasis at every disease stage.

109 t differences in time to mastectomy, time to distant metastasis, breast cancer-specific survival, or

110 reduced risk of metastasis is mainly due to distant metastasis but not regional lymphatic metastasis

111 CC is well known for perineural invasion and distant metastasis, but its underlying molecular mechani

112 CTC) have related properties associated with distant metastasis, but the mechanisms through which CSC

113 s are at elevated risk for local failure and distant metastasis, but the molecular hallmarks of tumor

114 Oxidative stress thus limits distant metastasis by melanoma cells in vivo.

115 /MRI correctly detected 3 (1%) patients with distant metastasis, CHCT/MRI detected 11 (4%) patients,

116 ho had radiotherapy had a lower incidence of distant metastasis compared with those who did not have

117 INTERPRETATION: That aspirin prevents distant metastasis could account for the early reduction

118 %; HR, 0.65; P = .07), respectively; 10-year distant metastasis cumulative incidences were 6% (95% CI

119 ositive results in 1%, and in no patient did distant metastasis develop.

120 The risks of nodal metastasis and distant metastasis did not differ significantly by PNI c

121 kers was significantly associated with worse distant metastasis disease-free survival (hazard ratio [

122 gnostic factor for recurrence-free survival, distant metastasis disease-free survival, and MSS after

123 Locoregional failure (LRF) and distant metastasis (DM) rates were estimated by using th

124 incidence (CCI) of local recurrence (LR) and distant metastasis (DM) were calculated.

125 non-muscle-invasive local failure (LF), and distant metastasis (DM) were estimated by the cumulative

126 Recurrence-free survival (RFS), distant metastasis (DM), and local recurrence (LR) rates

127 eoadjuvant treatment as locoregional (LR) or distant metastasis (DM).

128 e amounts of neuroepithelium and generated a distant metastasis entirely composed of rhabdomyoblasts.

129 This is mostly due to early local and distant metastasis, even after surgical resection.

130 en nadir + 2-ng/mL definition), freedom from distant metastasis (FFDM), cancer-specific survival (CSS

131 who had a clinical complete response without distant metastasis for 1 year was 93.8% (92.3-95.9), for

132 The probably of remaining free from distant metastasis for a further 2 years in patients who

133 patients remaining free of local regrowth or distant metastasis for an additional 2 years after susta

134 umulative incidences of local recurrence and distant metastasis for radical versus conservative group

135 our-initiating potential, local invasion and distant metastasis formation.

136 h, yet substantially increases migration and distant metastasis formation.

137 end points, including CR and bladder-intact distant metastasis free survival at 3 years (BI-DMFS3),

138 survival, including poorer overall survival, distant metastasis free survival, relapse free survival,

139 ression correlates with overall survival and distant metastasis free survival.

140 f a basal-like or TNBC phenotype and reduced distant metastasis free survival.

141 n species, and that these networks predicted distant metastasis free survival.

142 The 5-year distant-metastasis free survival was 94.9% for low-risk

143 aining a clinical complete response or being distant metastasis-free for 1, 3, and 5 years from the d

144 val was 83.7% (95% CI 72.6-94.9), the 2 year distant metastasis-free interval was 90.8% (82.2-99.5),

145 The association between GRPR expression and distant metastasis-free interval was also examined.

146 The 2-year local recurrence-free rate, distant metastasis-free rate, disease-free survival, and

147 atment samples on breast cancer-specific and distant metastasis-free survival (BCSS and DMFS, respect

148 l (OS), progression-free survival (PFS), and distant metastasis-free survival (DMFS) (Hazard Ratios [

149 Secondary end points were distant metastasis-free survival (DMFS) and overall surv

150 There was also an improvement in distant metastasis-free survival (DMFS) for SNB patients

151 ence-free survival (RFS; primary end point), distant metastasis-free survival (DMFS), and overall sur

152 datasets, where the objective is predicting distant metastasis-free survival (DMFS).

153 er was associated with significantly reduced distant metastasis-free survival (DMFS; P=0.01) and dise

154 odel revealed no significant differences for distant metastasis-free survival (hazard ratio [HR], 1.2

155 -regional control (HR, 0.04; P = 0.002), and distant metastasis-free survival (HR, 0.07; P = 0.028).

156 DeltaSUV1-3 was an independent predictor of distant metastasis-free survival (P = 0.01).

157 ff for DeltaSUV1-3 was the best predictor of distant metastasis-free survival (P = 0.05).

158 a combined prognostic score associated with distant metastasis-free survival (the time between rando

159 emical recurrence-free survival [bRFS], 29%; distant metastasis-free survival [DMFS], 53%; prostate c

160 (TNBC) patients have the worst prognosis and distant metastasis-free survival among all major subtype

161 Rates of distant metastasis-free survival and freedom from relaps

162 dule requires additional assessment based on distant metastasis-free survival and overall survival en

163 ints included 2-year local-regional control, distant metastasis-free survival and overall survival, a

164 Findings were similar for distant metastasis-free survival and overall survival.

165 HER2DX was significantly associated with distant metastasis-free survival as a continuous variabl

166 The rate of distant metastasis-free survival at 5 years was 48.3% in

167 th-free survival at 3 years, and conditional distant metastasis-free survival at 5 years.

168 The 5-year distant metastasis-free survival of the low-risk, medium

169 urrence-free survival, overall survival, and distant metastasis-free survival than placebo.

170 Distant metastasis-free survival was the primary end poi

171 rogression-free survival, local failure, and distant metastasis-free survival were not different betw

172 improvements in recurrence-free survival and distant metastasis-free survival with nivolumab versus i

173 and biologic factors, disease-free survival, distant metastasis-free survival, and overall survival (

174 ondary end points included overall survival, distant metastasis-free survival, and safety.

175 ondary end points included overall survival, distant metastasis-free survival, freedom from relapse,

176 Two-year local-regional control, distant metastasis-free survival, progression-free survi

177 ed overall survival, local and regional PFS, distant metastasis-free survival, quality of life, adver

178 w Foxa1 expressions are associated with poor distant metastasis-free survival.

179 and is associated with decreased overall and distant metastasis-free survival.

180 ntiation signatures and predicts overall and distant metastasis-free survival.

181 statistically significantly associated with distant metastasis-free survival.

182 nical outcomes included overall survival and distant metastasis-free survival.

183 gnature is a better prognostic indicator for distant metastasis-free survival.

184 ll, local recurrence-free, disease-free, and distant metastasis-free survivals (P = 0.033, 0.014, <0.

185 on is linked to an overall, disease-free and distant metastasis-free worse survival prognosis in brea

186 = 0.006), lymphatic-spread-free (P = 0.041), distant-metastasis-free (P = 0.029), and melanoma-specif

187 f SDPR correlates with significantly reduced distant-metastasis-free and relapse-free survival of bre

188 no significant difference between groups for distant-metastasis-free interval (HR 0.88, 95% CI 0.73-1

189 In the Erasmus Breast Cancer Cohort, 5-year distant-metastasis-free survival was longer in patients

190 s tumor growth, local metastasis burden, and distant metastasis frequency in this model of NEPC.

191 AST were independent predictors of recurrent distant metastasis from primary stage II or III colorect

192 ients were positive in the pelvis (group A), distant metastasis (group B) were detected in 72 of 605

193 95% CI 1.10-2.10), while patients with more distant metastasis had a 27% statistically non-significa

194 Patients with distant metastasis had no increase in disease-specific m

195 groups with low and high risk for developing distant metastasis (hazard ratio, 4.8; P = .0498, log-ra

196 igh in both TCRS and PRS had a lower risk of distant metastasis (HR, 0.69; 95% CI, 0.49 to 0.98).

197 (HR: 12.8, 95% CI: 3 to 49) and incidence of distant metastasis (HR: 8.7, 95% CI: 2 to 31) correlated

198 PET/CT was positive for pelvic LN or distant metastasis in 36 of 107 patients (33.6%).

199 at was significantly associated with risk of distant metastasis in a logistic regression model that a

200 n in vivo blocked primary tumor invasion and distant metastasis in a mouse model of basal breast canc

201 01 (everolimus) results in the occurrence of distant metastasis in a rat model of pancreatic cancer.

202 e long ectopic blood vessels and (c) enhance distant metastasis in a zebrafish xenograft model.

203 owever, two studies showed a reduced risk of distant metastasis in advanced nodal stage patients.

204 PDGFRalpha induces CSC invasion and promotes distant metastasis in advanced SCCs.

205 rates high specificity and PPV for detecting distant metastasis in cervical and endometrial cancer an

206 cell lines and was associated with nodal and distant metastasis in CRC patient samples.

207 pression is associated with a higher risk of distant metastasis in ER+ breast cancer patients.

208 r, lower expression of Notch1 was related to distant metastasis in GC patients with a borderline stat

209 dered the main cause of local recurrence and distant metastasis in lung cancer.

210 icantly preventing both local recurrence and distant metastasis in malignant melanoma models.

211 nd AURKA inhibitors impairs tumor growth and distant metastasis in mice harboring xenografts of breas

212 ncer patients to identify genes that promote distant metastasis in mice.

213 KPNA4 significantly reduces PCa invasion and distant metastasis in mouse models.

214 Antioxidants promoted distant metastasis in NSG mice.

215 tage, higher tumor grade and the presence of distant metastasis in PanNET patients.

216 t ultimately induce local tumor invasion and distant metastasis in PanNETs.

217 We established the frequency of distant metastasis in patients who developed cancer duri

218 The noninferior accuracy for diagnosis of distant metastasis in patients with common pediatric tum

219 correlated with the extent of lymph node and distant metastasis in patients with CRC and served as a

220 ron emission tomography (PET) for predicting distant metastasis in patients with early-stage non-smal

221 (PET)/computed tomography (CT) in detecting distant metastasis in patients with local-regionally adv

222 PET and applied it to track spontaneous and distant metastasis in the presence or absence of genotox

223 At 5 years, the rate of survival without distant metastasis in this group was 94.7% (95% confiden

224 association of one 3q driver gene FXR1 with distant metastasis in TNBC (P = 0.01) was further valida

225 ch adenocarcinomas and increased relapse and distant metastasis in triple-negative breast cancer.

226 estrogen-regulated gene expression, EMT, and distant metastasis in vivo, suggesting that AR may play

227 resulted in a higher incidence of local and distant metastasis in vivo.

228 CF, and relapse (locoregional failure [LRF], distant metastasis) in this patient group.

229 a (HNSCC) is that local invasion rather than distant metastasis is the major route for dissemination.

230 ssues, followed by the formation of local or distant metastasis, is a lethal hallmark of cancer.

231 rising the extent of disease in the order of distant metastasis (M), regional lymph node involvement

232 AF mutations, local recurrence, regional and distant metastasis, melanoma-related mortality, and all-

233 patients (3.4%) because of the occurrence of distant metastasis (n = 5) or other reasons.

234 ymph node involvement, and evidence of overt distant metastasis obtained by imaging technologies.

235 No disease progression, relapse, or distant metastasis occurred during follow-up.

236 In dogs and children distant metastasis occurs in >80% of individuals treated

237 l lymphangiogenesis, lymphatic invasion, and distant metastasis of breast cancer cells.

238 ion of SDF-1/CXCR4 and PDGFR pathways blocks distant metastasis of human PD/S-SCCs.

239 oPrint is able to predict the development of distant metastasis of patients with stage II colon cance

240 The C-index for 10-year distant metastasis of the clinical model alone was 0.76;

241 CI, 49 to 60) with placebo (hazard ratio for distant metastasis or death, 0.55; 95% CI, 0.44 to 0.70)

242 m in greatest dimension were associated with distant metastasis or death.

243 s with high Fuhrman grade, high tumor stage, distant metastasis or high pre-operative levels of C-rea

244 ted a significantly higher detection rate of distant metastasis or synchronous cancer than strategies

245 The true detection rate of distant metastasis or synchronous cancer with PET/CT was

246 ed with a reduced proportion of cancers with distant metastasis (OR 0.69, 95% CI 0.57-0.83, p(sig)<0.

247 mical failure, local or regional recurrence, distant metastasis, or death from any cause, or was cens

248 utcomes (local recurrence, nodal metastasis, distant metastasis, or death from skin cancer).

249 outcome (local recurrence, nodal metastasis, distant metastasis, or disease-specific death) of CSCCs

250 ognostic factors for cumulative incidence of distant metastasis (P < .001 and P = .035, respectively)

251 els compared to tumors from patients without distant metastasis (P < 0.001).

252 hrman grade, tumor stage and the presence of distant metastasis (P < 0.005).

253 T stage (P < 0.001), N stage (P = 0.023) and distant metastasis (P = 0.033).

254 lated with depth of invasion (P = 0.003) and distant metastasis (P = 0.0331), but only marginally wit

255 (P = 0.0259), the nodal status (P < 0.0001), distant metastasis (P = 0.0354), the stage (P < 0.0001),

256 tage (P<0.001), poor prognosis (P<0.001) and distant metastasis (P=0.008).

257 TNBC) has high rates of local recurrence and distant metastasis, partially due to its high invasivene

258 In addition, tumors from patients with known distant metastasis presented reduced NPM1 protein levels

259 was to test this hypothesis by comparing the distant metastasis rate (DMR) on initial (18)F-FDG PET/C

260 After 15 years of follow-up, distant metastasis rate, overall survival, and breast ca

261 for patients in the training cohort, 10-year distant metastasis rates for National Comprehensive Canc

262 ier clinical-genomic risk groups had 10-year distant metastasis rates of 3.5%, 29.4%, and 54.6%, for

263 have a poor prognosis and high incidence of distant metastasis, relative to other breast cancer subt

264 he results were correlated with metachronous distant metastasis risk (n = 22 patients).

265 , 1.03 to 1.45) and lethal disease (death or distant metastasis; RR, 1.19; 95% CI, 1.00 to 1.43).

266 can become aggressive tumors associated with distant metastasis, shortening survival.

267 HR], 1.37 [95% CI, 1.12 to 1.68], P = .002), distant metastasis (sHR, 1.40 [95% CI, 1.00 to 1.95], P

268 signatures and clinical outcomes, including distant metastasis, survival, and tumor grade.

269 ho had radiotherapy had a lower incidence of distant metastasis than did patients who did not have ra

270 nd subgroup differences were less marked for distant metastasis than for regional relapse.

271 nger duration of survival without relapse or distant metastasis than placebo with no apparent long-te

272 PET imaging characteristics associated with distant metastasis that could potentially help practitio

273 ure led to a 5-year rate of survival without distant metastasis that was 1.5 percentage points lower

274 Breast cancer cells facilitate distant metastasis through the induction of immunosuppre

275 to patients revealing no more than 1 type of distant metastasis to avoid confounding by other distant

276 ate-rich diet enhanced lung colonization and distant metastasis to lymph nodes and decreased overall

277 ry tumors and the microenvironment of future distant metastasis via tumor-derived factors.

278 Overall prevalence of distant metastasis was 13.7% (21 of 153) for cervical ca

279 Six-year rate of distant metastasis was 14% for AS + RT and 9.1% for AS +

280 ercentage of patients who were alive without distant metastasis was 65% (95% CI, 61 to 71) with dabra

281 The first site of distant metastasis was CNS only for 3.9% of patients, CN

282 Distant metastasis was highest in patients with RET/PTC-

283 No definitive association with distant metastasis was seen in multivariable Cox proport

284 tes of local tumor relapse, enucleation, and distant metastasis were 3.9%, 3.7%, and 13.4%, respectiv

285 ode metastasis, extrathyroidal invasion, and distant metastasis were also included in the model, the

286 A total of 11,541 cases with synchronous distant metastasis were analyzed.

287 of local treatment failure and occurrence of distant metastasis were determined.

288 Locoregional recurrence and distant metastasis were included as intermediate states,

289 n of VIP and VPAC1, advanced tumor stage and distant metastasis were independent prognostic factors.

290 Similar rates of survival without distant metastasis were reported in the subgroup of pati

291 Standard imaging modalities often detect distant metastasis when the burden of disease is high, u

292 liation because of locally advanced stage or distant metastasis, where it cannot be subjected to cura

293 c-Myc mice developed spontaneous HCC without distant metastasis, whereas Alb/AEG-1/c-Myc mice develop

294 ham histological grade, Ki67 expression, and distant metastasis, whereas high PIP4K2B expression stro

295 Distant metastasis, which results in >90% of cancer-rela

296 also promoted hematogenous dissemination and distant metastasis, which was linked to neuroblastoma ce

297 cant parameter to predict the development of distant metastasis with a hazard ratio of 4.28 (95% conf

298 romoted tumor angiogenesis and breast cancer distant metastasis without affecting primary tumor growt

299 1L2 knockdown, or MTHFD1 knockdown inhibited distant metastasis without significantly affecting the g

300 rval for the rate of 5-year survival without distant metastasis would be 92% (i.e., the noninferiorit